Efficacy and Safety of Eribulin for Breast Cancer Liver Metastasis, 2020-2024

A single-center retrospective study from the First Affiliated Hospital of Zhengzhou University analyzed 73 breast cancer patients with liver metastases treated with eribulin between 2020 and 2024. The dataset includes progression-free survival and objective response rate assessments per RECIST 1.1, along with adverse event profiles. It was authored by Zishuo Wang and shared under a CC-BY-4.0 license.

Use Cases

• Evaluate real-world progression-free survival based on the reported median of 3.7 months.
• Compare objective response rates across breast cancer subtypes, such as the HR+/HER2− subtype.
• Profile common adverse events like neutropenia, fatigue, alopecia, and peripheral neuropathy.
• Assess the safety profile of eribulin therapy in a heavily pre-treated patient population.

Strengths

• Contains data from 73 patients, providing a specific cohort size.
• Reports specific clinical metrics: median progression-free survival of 3.7 months and an objective response rate of 15.1%.
• Includes detailed adverse event rates, such as neutropenia (42.5%) and fatigue (37.0%).

Limitations

• Row count and column-level documentation are absent; field semantics must be inferred after download.
• Data is from a single center, which may limit generalizability.
• The dataset is small (136.2 KB), indicating a limited scope.

Provenance

Source

First Affiliated Hospital of Zhengzhou University

Collection Method

Retrospective analysis of patient records.

Time Range

2020 to 2024

Freshness

Last updated 2026-05-12 04:18:57

Geography

China